Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melphalan plus daratumumab conditioning vs melphalan alone for high-risk multiple myeloma undergoing autologous HSCT
ChiCTR2100052302Phase 4Not yet recruiting
- Sponsor
- Hematology Center of the First Affiliated Hospital of Xinjiang Medical University
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in multiple myeloma (MM) comparing Melphalan + daratumumab conditioning with Melphalan conditioning (2 arms). Primary endpoint: Blood routine. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
daratumumabmelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2100052302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052302.